“Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis”, J of Skin, vol. 9, no. 6, p. s601, Nov. 2025, doi: 10.25251/14pn6v71.